Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Panobinostat vs placebo after autologous stem cell transplant in Hodgkin lymphoma
2009-014846-26Phase 3Completed
- Sponsor
- Novartis
- Start
- Feb 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in classical Hodgkin lymphoma (cHL) comparing Panobinostat maintenance with Placebo (2 arms). Primary endpoint: Disease-free survival. Started Feb 2010; status: completed.
02
Drugs
panobinostat
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on 2009-014846-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-014846-26.